Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

Part of paid clinical trials in Santa Monica, California.

Sponsor
Sarcoma Oncology Research Center, LLC
Study ID
NCT07671534
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumor Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Gemcitabine — DRUG
    600 mg/m2 (Max: 1000 mg) i.v. on D1, D8, D15
  • Mitomycin C — DRUG
    Mitomycin C 14 mg i.v. every 6 weeks
  • Thalidomide — DRUG
    Thalidomide 100 mg daily x 15 days

Study Details

This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.

Key Dates

Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2029
Completion
Jun 30, 2029

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    Gemcitabine 600 mg/m2 (Max: 1000 mg) i.v. on D1, D8, D15; Mitomycin C 14 mg i.v. every 6 weeks; Thalidomide 100 mg p.o. daily x 15 days

Primary Outcome Measure

Progression Free Survival (PFS) [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Sarcoma Oncology Research Center / Cancer Center of Southern CaliforniaSanta MonicaCalifornia90403
Erlinda M. Gordon, MD
[email protected]
3105529999
Victoria Chua-Alcala, MD
[email protected]
3105529999
Sant P. Chawla, MD (SUB_INVESTIGATOR)
Erlinda M. Gordon, MD (SUB_INVESTIGATOR)
Doris Quon, MD, PhD (SUB_INVESTIGATOR)
Steven G. Wong, MD (SUB_INVESTIGATOR)
Ania Moradkhani, NP (SUB_INVESTIGATOR)
Ted Kim, PA (SUB_INVESTIGATOR)

Find similar trials in Santa Monica, CA

By research site
Sarcoma Oncology Research Center / Cancer Center of Southern California· Santa Monica, CA

Related Studies